ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) announced that updated results from its Phase 2 ASPEN-06 clinical trial will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The trial evaluates evorpacept, a CD47-blocking therapeutic, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel for treating HER2-positive gastric/gastroesophageal junction cancer patients who previously received anti-HER2 therapy.
The presentation will be delivered by Dr. Kohei Shitara from the National Cancer Center Hospital East in Japan on January 23, 2025. The study results will be presented during the Rapid Oral Abstract Session focusing on Cancers of the Esophagus and Stomach.
Positive
- Selection for oral presentation at major medical conference indicates potential significance of trial results
- Trial advances company's development in HER2-positive gastric cancer treatment
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALXO gained 2.79%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.
The updated results from the ASPEN-06 study will be detailed in the following oral presentation:
Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)
Abstract Number: 332
Presenter: Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in Japan
Presentation Date and Time: Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PST
Session Information: Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
Location: Level 2 Ballroom
Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
What is the Phase 2 ASPEN-06 trial testing for ALXO's evorpacept?
When will ALXO present the ASPEN-06 trial results at ASCO GI 2025?
What is evorpacept's mechanism of action in ALXO's cancer treatment?
Who will present ALXO's ASPEN-06 trial results at ASCO GI 2025?
